• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Keywords » mood_stabilizers

Items Tagged with 'mood_stabilizers'

ARTICLES

Brexpiprazole Ineffective in Mania

September 28, 2021
Richard Moldawsky, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Richard Moldawsky, MD. Dr. Moldawsky has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Choosing an antipsychotic in bipolar disorder just got more complicated. This series of industry-sponsored trials reveals that their anti-manic activity may not be a class effect.
Read More

Maintenance Pharmacotherapy of Bipolar Disorder: How Long Is Long Enough?

May 4, 2021
Nicholas Rosenlicht, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Nicholas Rosenlicht, MD. Dr. Rosenlicht has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Textbooks tell us that patients with bipolar I disorder need to take mood stabilizers for life. But what are the real risks of stopping these medications? A new meta-analysis provides some clarity.
Read More
CLINICAL UPDATE

How to Use Lamotrigine

January 1, 2021
Chris Aiken, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Chris Aiken, MD. Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Lamotrigine is approved for the prevention of bipolar episodes, but Dr. Aiken explains why it may also treat active bipolar depression. This mood stabilizer is among the most tolerable in its class, and has additional benefits in OCD, borderline personality disorder, and depersonalization disorder.
Read More

Which Medications Have the Lowest Risk of Side Effects?

October 30, 2020
Pavan Madan, MD.
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Pavan Madan, MD. Dr. Madan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
When we choose medications, we typically think that we are paying attention to risks and benefits. But what happens when we just look through the lens of side effects? An entirely different picture emerges of what medications might be the better picks. You will be surprised and intrigued by this review of a very helpful study that will probably change your prescribing patterns.
Read More

Mood Stabilizers: What You Don’t Know Can Hurt Them

October 6, 2020
Nicholas Rosenlicht, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Nicholas Rosenlicht, MD. Dr. Rosenlicht has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
There are many mood stabilizers to choose from, but which ones are the best tolerated? This meta-analysis looks at how they stack up in terms of weight gain, sedation, and overall discontinuation.
Read More

Who Should Get Lithium?

September 3, 2020
Janusz Rybakowski, MD, PhD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Janusz Rybakowski, MD, PhDJanusz Rybakowski, MD, PhD

Janusz Rybakowski is a pioneer in lithium research who has authored over 500 articles on clinical psychiatry. He is a professor of psychiatry at Poznan University in Poland, former chairman of psychiatry at the Medical Academy Bydgoszcz, and author of an upcoming textbook on lithium. Dr. Rybakowski has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Some patients respond so well to lithium that they rarely need other interventions. Janusz Rybakowski sums up what we know about the optimal lithium responder, how to use this underutilized medication, and what lithium’s antiviral properties mean in the era of COVID-19.
Read More
RESEARCH UPDATE

Two Augmentation Strategies Compared in Bipolar I

September 3, 2020
Richard Moldawsky, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Richard J. Moldawsky, MD. Dr. Moldawsky has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Carbamazepine or valproic acid? Both have been used to augment lithium for decades, but which one works best? A new trial tests them head-to-head.
Read More

The Psychopharmacology Algorithm Project

March 30, 2020
David Osser, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
David Osser, MDDavid Osser, MD

General Editor of the Psychopharmacology Algorithm Project at the Harvard South Shore Psychiatry Residency Training Program and Associate Professor of Psychiatry at Harvard University. Dr. Osser has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Dr. Osser set out to develop a psychopharmacology algorithm that actually changes practice. He speaks to us on antidepressants in bipolar, psychoses that don’t need antipsychotics, and his top picks for bipolar mania, bipolar depression, and unipolar depression.
Read More

Oxcarbazepine: Close, but no Cigar

March 9, 2020
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Oxcarbazepine is thought of as a kinder, gentler cousin of carbamazepine, but it brings new safety issues of its own and does not fully escape the drug interactions that hinder carbamazepine. We pull on the published and unpublished trials to figure out where this anticonvulsant stands in bipolar disorder.
Read More

Psychopharmacology in Bipolar II

March 9, 2020
Tammas Kelly, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Tammas Kelly, MDTammas Kelly, MD

Psychiatrist in private practice in Fort Collins, CO. Author of The Art and Science of Thyroid Supplementation for the Treatment of Bipolar Depression (2018) Dr. Kelly has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Bipolar II is a different illness from Bipolar I, but it’s in Bipolar I that most of the psychopharmacology research was undertaken. Dr. Kelly walks us through some of the nuances in applying that knowledge to Bipolar II, and shows us how to recognize the subtle traces of hypomania and mixed features that go along with Bipolar II depression.
Read More
More Articles Tagged with 'mood_stabilizers'
Introducing Carlat Total Access Subscriptions

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    Treating Alcohol Use Disorder: A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.